Abstract:As advancements in the field of nanoparticle imaging science are made, one of the first benefits will be in open and endoscopic conditions. There is considerable evidence indicating that the use of injected contrast agents can improve the detection of tumor margins and small metastases. New and innovative targeting and contrast agents including small molecules, antibodies and nanoparticles have to be developed for a broad range of tumor types such as breast, brain, pancreatic, and ovarian cancers. At present, a number of organic dye molecules have been approved for human use including (1) indocyanine green (ICG), a near-infrared fluorescent dye; (2) fluorescein, a green fluorescent dye; (3) photofrin, a mixture of fluorescent protoporphyrin oligomers approved for photodynamic therapy, and (4) 5-aminolevulinic acid (ALA), a small molecule that is preferentially taken up by tumor cells leading to biosynthesis and accumulation of protoporphyrin IX, a natural fluorophore with red fluorescence emission. On the other hand, nanoparticles have not received FDA approval for clinical imaging, as this technology needs a lot of development and lot of research is being carried out in this unexplored area. A major task is, therefore to develop biocompatible and nontoxic nanoparticle contrast agents with the potential for FDA approval and human use. Such agents need to show improved sensitivity and specificity for tumor imaging in comparison with small-molecule-dyes. In this regard, it is highly promising to develop smart or activatable nanoparticles with improved pharmacokinetic, tumor targeting and organ clearance properties, based on the use of natural, biodegradable polymers (dextran and heparin). Dextran-based particles are sensitive to pH, and can be rapidly broken down under acidic conditions. Under neutral or slightly basic conditions, on the other hand, the dextran nanoparticles are stable and are able to circulate systemically in blood for 14 to 15 hours. In contrast, self-assembled heparin nanoparticles have much shorter blood circulation half-lives (about 60-80 min). For intra-operative use, this short circulation time could be beneficial because the probes will be cleared from the body quickly, so that surgical operations and treatment can start without much delay or waiting. For near-term clinical applications, it is important that both the dextran and heparin particles are able to trap as FDA-approved dye (such as indocyanine green), leading to new class of imaging contrast agents with improved bio distribution and photo physical properties. This class of nanoparticle contrast agents could also be conjugated with tumor targeting ligands such as folate, Epidermal Growth Factor (EGF), or RGD (recognition sequence for integrins that contains Arg-Gly-Asp attachment site) for improved sensitivity and specificity in perfect cancer imaging technique agents. This review article actually highlights the new developments occurring in this area of imaging techniques in cancer research and the author himself is using the technique for developing newer fluorescent molecules for molecular imaging using nanotechnology.

Performance of near-infrared dyes as effective contrast agents for breast cancer detection through simulation of photoacoustic imaging

Semiconducting Polymer Nanoparticles for Centimeters-Deep Photoacoustic Imaging in the Second Near-Infrared Window

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Indocyanine green enhanced co-registered diffuse optical tomography and photoacoustic tomography

In Vivo Photoacoustic Molecular Imaging of Breast Carcinoma with Folate Receptor-Targeted Indocyanine Green Nanoprobes

Near-infrared Dye-Loaded Magnetic Nanoparticles As Photoacoustic Contrast Agent for Enhanced Tumor Imaging

Targeted Blue Nanoparticles As Photoacoustic Contrast Agent for Brain Tumor Delineation

Biomedical Applications of Photoacoustic Imaging with Exogenous Contrast Agents

Exogenous Contrast Agents in Photoacoustic Imaging: An In Vivo Review for Tumor Imaging

Dextran based pH-sensitive near-infrared nanoprobe for in vivo differential-absorption dual-wavelength photoacoustic imaging of tumors

Advancements in Tumor Diagnostics through Carbon Dot‐Assisted Photoacoustic Imaging

A Photoacoustic Contrast Nanoagent with a Distinct Spectral Signature for Ovarian Cancer Management

Characterization of the In-Vivo Uptake of Novel Contrast Agents Using Photoacoustic Radiofrequency Spectra

Assessment of photoacoustic tomography contrast for breast tissue imaging using 3D correlative virtual histology

Intraoperative Identification and Guidance of Breast Cancer Microfoci Using Ultrasound and Near-Infrared Fluorescence Dual-Modality Imaging

Identification and usage of fluorescent probes as nanoparticle contrast agents in detecting cancer

Integration of Multitargeted Polymer-Based Contrast Agents with Photoacoustic Computed Tomography: An Imaging Technique to Visualize Breast Cancer Intratumor Heterogeneity

Antibody-Conjugated Polymersomes with Encapsulated Indocyanine Green J-Aggregates and High Near-Infrared Absorption for Molecular Photoacoustic Cancer Imaging

Novel Breast Cancer Detection System Combining Both Thermoacoustic (TA) and Photoacoustic (PA) Tomography Using Carbon Nanotubes (cnts) As a Dual Contrast Agent

Photoacoustic image patterns of breast carcinoma and comparisons with Magnetic Resonance Imaging and vascular stained histopathology

Application of near-infrared dyes for tumor imaging, photothermal, and photodynamic therapies.